Study of noninvasive retinal imaging device presented at Alzheimer's conference
News Jul 14, 2014
Preliminary results show the device, created at Cedars-Sinai and developed by NeuroVision Imaging, may provide highly predictive early detection of changes associated with Alzheimer's disease
A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.
The researchers present their findings July 15 in an oral presentation at the Alzheimer's Association International Conference 2014 in Copenhagen, Denmark. They also were invited by conference organizers to participate in a "breaking news" news conference on July 13.
"In preliminary results in 40 patients, the test could differentiate between Alzheimer's disease and non-Alzheimer's disease with 100 percent sensitivity and 80.6 percent specificity, meaning that all people with the disease tested positive and most of the people without the disease tested negative. The optical imaging exam appears to detect changes that occur 15-20 years before clinical diagnosis. It's a practical exam that could allow testing of new therapies at an earlier stage, increasing our chances of altering the course of Alzheimer's disease," said Shaun Frost, a biomedical scientist and the study manager at the Commonwealth Scientific and Industrial Research Organisation. CSIRO is Australia's national science agency.
Frost, first author of the AAIC 2014 abstract, will make the oral presentation. He said 120 participants of a full study of 200 had completed testing.
Keith Black, MD, professor and chair of Cedars-Sinai's Department of Neurosurgery, director of the Maxine Dunitz Neurosurgical Institute and the Ruth and Lawrence Harvey Chair in Neuroscience, said the accumulation of beta-amyloid plaque in the brain is a hallmark sign of Alzheimer's, but current tests detect changes only after the disease has advanced to late stages. Researchers believe that as treatment options improve, early detection will be critical, but existing diagnostic methods are inconvenient, costly and impractical for routine screening.
"PET scans require the use of radioactive tracers, and cerebrospinal fluid analysis requires that patients undergo invasive and often painful lumbar punctures, but neither approach is quite feasible, especially for patients in the earlier stages of disease," he said. Positron emission tomography, or PET, is the current diagnostic standard.
"The retina, unlike other structures of the eye, is part of the central nervous system, sharing many characteristics of the brain. A few years ago, we discovered at Cedars-Sinai that the plaques associated with Alzheimer's disease occur not only in the brain but also in the retina. By 'staining' the plaque with curcumin, a component of the common spice turmeric, we could detect it in the retina even before it began to accumulate in the brain. The device we developed enables us to look through the eye – just as an ophthalmologist looks through the eye to diagnose retinal disease – and see these changes."
This clinical trial was designed to enable researchers to correlate retinal plaque detected by optical imaging with brain plaque detected by PET scans. Studies involved patients diagnosed with Alzheimer's, a group with mild cognitive impairment and a group of people with no evidence of brain abnormality.
The retinal beta-amyloid plaque findings and optical imaging technology began at Cedars-Sinai with studies in live rodents and the post-mortem investigation of human retinas of people who had died with Alzheimer's. Maya Koronyo-Hamaoui, PhD, assistant professor of neurosurgery in the Department of Neurosurgery and the Department of Biomedical Sciences, and Yosef Koronyo, a research scientist, were first authors of the original results that were published in a journal and presented at the AAIC in 2010. The Australian study is one of several in progress to determine if similar results can be confirmed in humans living with the disease.
"This large double-blind clinical trial appears to validate our novel human retinal amyloid imaging approach using curcumin labeling. It further demonstrates significant correlation with brain amyloid burden, thereby predicting accumulation of plaques in the brain through the retina," said Koronyo-Hamaoui, a faculty principal investigator and head of the Neuroimmunology and Retinal Imaging Laboratory at Cedars-Sinai.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Researchers Find a Way to Separate Side Effects of Opioid Drugs Reducing RiskNews
Scientists have discovered a way to separate these two effects -- pain relief and breathing, opening a window of opportunity to make effective pain medications without the risk of respiratory failure.READ MORE
Biological Mechanism of a Leading Cause of Childhood Blindness RevealedNews
Scientists have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE